Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial
SGLT2 inhibitors are a promising treatment option in patients with heart failure. The Empire HF trial is registered with ClinicalTrials.gov and EudraCT. Treatment resulted in reductions in estimated extracellular volume, plasma volume, and measured GFR compared with placebo.
